Ingredient comparison
Berberine vs Metformin
Head-to-head on our evidence, safety, and hype axes - decisive where the data separate, honest where they do not. Not medical advice.
- Ev
- 72
- Safety
- 58
- Hype
- 64
Alkaloid with meaningful glucose/lipid trial signals; interacts like a pharmacologically active compound - respect drug interactions.
Full verdict →- Ev
- 82
- Safety
- 42
- Hype
- 72
Prescription diabetes medication sometimes discussed as a longevity drug; supplement positioning is misleading - this is a pharmaceutical with real contraindications.
Full verdict →At a glance
Metformin is a prescription antihyperglycemic with deep outcome literature in appropriate populations; berberine is an OTC alkaloid with overlapping metabolic interest but different monitoring, dosing, and interaction rules. Substituting one for the other without supervision is unsafe - compare them as distinct tools, not duplicates.
Overview
Berberine: Berberine is closer to a drug-like supplement: promising metabolic trials, but not casual candy - CYP interactions and GI effects matter.…
Metformin: Metformin is evidence-based for type 2 diabetes; longevity claims in healthy adults are speculative and not standard care.…
Berberine leads the composite (69 vs 58), but check evidence, safety, and hype separately - Metformin may still be the better fit.
Key differences
Derived from score gaps and verdict bands - not brand marketing.
- Evidence scores are within 6 points (72 vs 82) - neither ingredient clearly dominates trial breadth in our rubric.
- Safety scores favor Berberine (58 vs 42; Δ16) in our conservative read - not a personal guarantee.
- Hype gap is similar (64 vs 72); treat aggressive marketing skeptically for both.
- Verdict labels differ: “Promising” vs “Caution” - that captures overall band and safety gates, not a prescription.
Comparison table
Higher is better for overall, evidence, and safety. For hype gap, lower is better (less marketing ahead of trials).
| Metric | Berberine | Metformin | Lean |
|---|---|---|---|
| Overall | 69 | 58 | Too close to call |
| Evidence | 72 | 82 | Too close to call |
| Safety | 58 | 42 | Berberine (+16) |
| Hype gap | 64 | 72 | Too close to call |
| Verdict | Promising | Caution | Different bands |
Lean: Overall: Too close to call · Evidence: Too close to call · Safety: Berberine (+16) · Hype gap: Too close to call · Verdict: Different bands
Evidence comparison
Human trial breadth and quality for the outcomes people actually shop for - compressed from each hub.
Berberine
Several human trials for glycemic and lipid markers; heterogeneity and industry funding patterns exist.
Metformin
Strong for glycemic control; mixed animal longevity signals; human healthy-aging trials ongoing - not settled.
Safety comparison
Tolerability, vulnerable groups, and interaction signals we flag at typical contexts of use.
Berberine
GI upset common; contraindications in pregnancy; CYP3A4 interaction potential.
Metformin
Lactic acidosis risk contexts (renal failure, acute illness protocols), B12 deficiency with chronic use, GI intolerance.
Hype comparison
Where storefront and social claims outrun what trials support - higher hype gap means more disconnect.
Berberine
High longevity-bio influencer hype; evidence is real but not consequence-free.
Metformin
High longevity hype outside diabetes indications.
Who each is better for
Heuristic fit from our rubric - not personalized medical advice. Check each hub for avoid lists and interactions.
Bottom line
Call it a split decision on the composite: Berberine and Metformin land too close to crown one ingredient outright. Clearest tilts: Berberine on safety. Read both full verdict pages before changing doses or stacking; our scores compress complexity and are not medical advice.
Full ingredient write-ups
Mechanisms, dosing notes, avoid lists, and sources live on each hub.
Best lists
Ranked guides where one of these ingredients is pinned or featured.